Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26766540)
Watch
English
New developments for antibody-drug conjugate-based therapeutic approaches
scientific article
In more languages
edit
Statements
instance of
scholarly article
0 references
title
New developments for antibody-drug conjugate-based therapeutic approaches
(English)
0 references
main subject
antibody
1 reference
based on heuristic
inferred from title
author name string
Bart Ecg de Goeij
series ordinal
1
0 references
John M Lambert
series ordinal
2
0 references
language of work or name
English
0 references
publication date
June 2016
0 references
published in
Current Opinion in Immunology
0 references
volume
40
0 references
page(s)
14-23
0 references
cites work
Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-CD30 Antibodies for Hodgkin lymphoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maytansine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of selected natural products as therapeutic agents against cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Physiological parameters in laboratory animals and humans
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cysteine cathepsins: multifunctional enzymes in cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Microtubule-binding agents: a dynamic field of cancer therapeutics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Head and neck cancer cells and xenografts are very sensitive to palytoxin: decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The development of pyrrolobenzodiazepines as antitumour agents
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/J.COI.2016.02.008
0 references
PubMed publication ID
26963132
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
